RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
-18.69%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$714M
AUM Growth
+$714M
(-22%)
Cap. Flow
-$1.38M
Cap. Flow
% of AUM
-0.19%
Top 10 Holdings %
Top 10 Hldgs %
30.92%
Holding
97
New
3
Increased
39
Reduced
32
Closed
12
Top Buys
| 1 |
AbbVie
ABBV
|
$9.14M |
| 2 |
Zimmer Biomet
ZBH
|
$8.09M |
| 3 |
CVS Health
CVS
|
$7.11M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$6.66M |
| 5 |
UnitedHealth
UNH
|
$5.49M |
Top Sells
| 1 |
DERM
Dermira, Inc.
DERM
|
$12.1M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$10.7M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$10.1M |
| 4 |
Humana
HUM
|
$6.91M |
| 5 |
Becton Dickinson
BDX
|
$4.6M |
Sector Composition
| 1 | Healthcare | 96.22% |
| 2 | Energy | 0.06% |
| 3 | Technology | 0.03% |
| 4 | Financials | 0.02% |
| 5 | Consumer Discretionary | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $29.6M | 4.15% | 1,000,000 +225,000 | +29% | +$6.66M |
|
|
2
Vertex Pharmaceuticals
VRTX
$100B
| $27.4M | 3.83% | 115,000 -45,000 | -28% | -$10.7M |
|
|
3
AbbVie
ABBV
$372B
| $25.1M | 3.52% | 330,000 +120,000 | +57% | +$9.14M |
|
4
NovoCure
NVCR
$1.38B
| $24.2M | 3.4% | 360,000 +10,000 | +3% | +$673K |
|
|
5
UnitedHealth
UNH
$281B
| $20M | 2.79% | 80,000 +22,000 | +38% | +$5.49M |
|
6
Bristol-Myers Squibb
BMY
$96B
| $19.5M | 2.73% | 350,000 +10,000 | +3% | +$557K |
|
7
Nektar Therapeutics
NKTR
$568M
| $19.2M | 2.69% | 1,075,000 -25,000 | -2% | -$446K |
|
8
Esperion Therapeutics
ESPR
$448M
| $18.7M | 2.62% | 592,798 -67,202 | -10% | -$2.12M |
|
9
Cigna
CI
$80.3B
| $18.6M | 2.61% | 105,000 +10,000 | +11% | +$1.77M |
|
10
Boston Scientific
BSX
$156B
| $18.4M | 2.58% | 565,000 +113,332 | +25% | +$3.7M |
|
11
BioMarin Pharmaceuticals
BMRN
$11.2B
| $15.6M | 2.19% | 184,845 -25,155 | -12% | -$2.13M |
|
|
12
CVS Health
CVS
$92.8B
| $15.4M | 2.16% | 260,000 +119,786 | +85% | +$7.11M |
|
13
Elevance Health
ELV
$71.8B
| $14.8M | 2.07% | 65,000 +3,000 | +5% | +$681K |
|
|
ALXN
14
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $14.4M | 2.01% | 160,000 +18,681 | +13% | +$1.68M |
|
|
15
Humana
HUM
$36.5B
| $14.1M | 1.98% | 45,000 -22,000 | -33% | -$6.91M |
|
16
Eli Lilly
LLY
$657B
| $13.9M | 1.94% | 100,000 -11,446 | -10% | -$1.59M |
|
17
Abbott
ABT
$231B
| $13.4M | 1.88% | 170,000 -37,469 | -18% | -$2.96M |
|
|
ABMD
18
DELISTED
Abiomed Inc
ABMD
| $12.8M | 1.79% | 88,000 +1,000 | +1% | +$145K |
|
19
Merck
MRK
$210B
| $12.7M | 1.78% | 165,000 +5,000 | +3% | +$385K |
|
20
Guardant Health
GH
$8.41B
| $12.2M | 1.71% | 175,000 +19,732 | +13% | +$1.37M |
|
21
Jazz Pharmaceuticals
JAZZ
$7.75B
| $12M | 1.68% | 120,000 +19,195 | +19% | +$1.91M |
|
|
AXNX
22
DELISTED
Axonics, Inc. Common Stock
AXNX
| $11.8M | 1.66% | 465,000 +135,000 | +41% | +$3.43M |
|
23
Medtronic
MDT
$119B
| $11.8M | 1.65% | 130,780 +5,750 | +5% | +$519K |
|
24
Intuitive Surgical
ISRG
$170B
| $11.4M | 1.6% | 23,000 +11,000 | +92% | +$5.45M |
|
25
Neurocrine Biosciences
NBIX
$13.8B
| $11.3M | 1.58% | 130,000 +10,000 | +8% | +$866K |
|